Blosozumab
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis[1][2].
Product Specifications
CAS Number
1132758-87-2
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/blosozumab.html
Purity
99.45
Solubility
10 mM in DMSO
Smiles
[Blosozumab]
Molecular Weight
(144.88 kDa)
References & Citations
[1]Robert R Recker, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015 Feb;30 (2) :216-24. |[2]Daniel G Rudmann, et al. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125 (2) :586-94.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
